Platinum-resistant ovarian cancer (PROC) remains one of the most significant challenges in gynecologic oncology; however, novel antibody-drug conjugates (ADCs) and innovative investigational therapies are opening new avenues to improve outcomes.
Join two leading ovarian cancer experts for this live webinar to dive deeper into the latest clinical data on emerging agents, including novel targets and mechanisms of action, and examine their impact on treatment selection and sequencing. Examine barriers that impede equitable clinical trial enrollment and uncover strategies to expand access and enhance participation of underrepresented populations. Elevate your practice with the PROCure Emerging Therapies Clinical Trial Pocket Guide, a downloadable tool to support timely referrals and informed treatment decisions.